Clinical Trials Logo

Pediatric Cancer clinical trials

View clinical trials related to Pediatric Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04719416 Withdrawn - Pediatric Cancer Clinical Trials

Relaxation Therapy in Pediatric Oncology

Start date: September 2022
Phase: N/A
Study type: Interventional

This study will look at the use of relaxation therapy in children with cancer. The study will compared patients who are current receiving treatment for their cancer and those who are currently in remission. Patients will be asked to listen to a short audio recording twice a week prior to going to bed which will walk patients through a mediation session. Surveys will be distributed through parental emails on the first of each month for each child to complete for the duration of 12 months. It is anticipated that the use of relaxation therapy will help to improve anxiety and pain levels in this population.

NCT ID: NCT04044378 Withdrawn - Pediatric Cancer Clinical Trials

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Start date: August 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Results of previous study showed high objective response but short-term activity of anti-angiogenesis tyrosine kinase inhibitors in advanced osteosarcoma. Given the recent success of immunotherapies, combinations of antiangiogenics with immune checkpoint blockers have become an attractive strategy. The investigators had completed an prospective phase 2 trial of the combination of apatinib and camrelizumab on advanced osteosarcoma and showed prolonged progression-free survival for this combination. Famitinib is a novel tyrosine kinase inhibitor targeting VEGFR-2, -3 and FGFR-1, -2, -3, -4 with high affinity, which showed broad antitumor activity against a variety of xenograft models. A Study to Compare the Efficacy and Safety of Levatinib with or without Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma showed promising median PFS of 11.3 months. Thus we also try to investigate the combination efficacy of TKIs with chemotherapy in advanced osteosarcoma. This study aims to investigate the recommended phase 2 dose for pediatric use of famitinib in combination with camrelizumab and trys to explore the efficacy and safety for single drug famitinib, famitinib and camrelizumab and famitinib and ifosfamide in patients with inoperable high-grade osteosarcoma progressing after chemotherapy.

NCT ID: NCT03127254 Withdrawn - Pediatric Cancer Clinical Trials

Can Making Video Narratives Benefit Adolescents With Cancer

Start date: March 5, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about the content of and benefits of making video testimonials in adolescents with cancer.

NCT ID: NCT01828502 Withdrawn - Pediatric Cancer Clinical Trials

Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer

Start date: October 2013
Phase: Phase 2
Study type: Interventional

RATIONALE: Providing parent/caregivers of children with cancer with education and evidence of secondhand smoke exposure can protect the child from future exposure to tobacco smoke. PURPOSE: This randomized study will compare education only to education plus cotinine feedback in decreasing secondhand smoke exposure in pediatric patients with cancer that reside with a household smoker.